9th International Conference on ^{Genomics and Pharmacogenomics} June 15-16, 2017 London, UK

Yuri Dubrova grew up in Kiev, Ukraine. He did his undergraduate degree in Biology at Kiev State University (Ukraine), and PhD and DrSci in Genetics at NI Vavilov Institute of General Genetics, Moscow. In 1994 he moved to Leicester.

Professor Yuri Dubrova’s research interests focus on the analysis of germline mutation induction in humans and mice following exposure to ionising radiation, chemical mutagens and some anticancer drugs. His recent research has also involved transgenerational genomic instability manifesting in the offspring of exposed parents.

Henry M. Sobell completed his studies at Brooklyn Technical High School (1948-1952), Columbia College (1952-1956), and the University of Virginia School of Medicine (1956-1960). Instead of practicing clinical medicine, he then went to the Massachusetts Institute of Technology (MIT) to join Professor Alexander Rich in the Department of Biology (1960-1965), where, as a Helen Hay Whitney Postdoctoral Fellow, he learned the technique of single crystal X-ray analysis. He then joined the Chemistry Department at the University of Rochester, having been subsequently jointly appointed to both the Chemistry and Molecular Biophysics departments (the latter at the University of Rochester School of Medicine and Dentistry), becoming a full tenured Professor in both departments (1965-1993). He is now retired and living in the Adirondacks in New York, USA.

Chemistry and Molecular Biophysics

Prof. Kumar is a molecular cancer biologist with a particular focus on breast cancer progression. Overall, Prof. . Kumar has made conceptual advances in connecting extracellular signaling to gene expression to cancer phenotypes, and paved the way for new directions in biomedical research. Prof. Kumar’s research has illustrated in 16 Covers in the major Cancer Research journals. He has received several awards for his research work. Prof. Kumar has authored over 292 peer-reviewed articles, and Edited or Co-Edited 6 Books/Volumes in the areas of cancer signaling and therapeutics. Prof. Kumar has trained about 70 students, fellows and junior faculty, and was actively involved in training and mentoring physician-scientists. Prof. Kumar has shared his knowledge by delivering about 230 invited, keynote or plenary lectures at academic institutions, and national and international scientific conferences. Prof. Kumar has been serving on multiple peer-review national and international funding panels, and on the editorial boards of leading cancer journals.

Mechanisms of breast cancer progression and metastasis, and hormone-independence with a special emphasis on phenotypic signaling, chromatin remodeling, and targeted therapeutics

Dr. Nickerson obtained a Ph.D. in Molecular Medicine from the George Washington University. He has made significant contributions to disease gene identification using positional cloning, including an altered Birt-Hogg-Dubé gene in chromophobe RCC, fumarate hydratase in papillary RCC, the dead-end gene in testicular cancer, and the UBIAD1 gene in Schnyder Corneal Dystrophy. More recently, he has sequenced urologic tumor genomes and identified alterations in TET2 in prostate cancer and the BRCA pathway in bladder and kidney cancer, which have been translated to a clinical trial starting in 2016. He is an active participant in Precision Medicine, ClinVar and the TCGA project.

Urologic Cancer Genetics, Genetics of Bladder Cancer, Genetics of Prostate Cancer, Genetics of Kidney Cancer.

Dr. Lamba, Ph.D., is an Associate Professor of the Department of Pharmacotherapy and Translational Research. Dr. Lamba did Ph.D in the field of Pharmacogenomics from Postgraduate Institute of Medical Education and Research in Chandigarh, India and did post-doctoral training at St. Jude Children’s Research Hospital, Memphis; TN.Dr. Lamba’s research has been funded from NIH/NCI since 2008 and focuses on identification, characterization and clinical validation of genomic/epigenomic markers predictive of therapeutic outcome in cancer patients specifically Acute Myeloid Leukemia. Her research spans from preclinical basic research comprising the discovery phase to translational/clinical phase in patient populations from multi-institute clinical trials.

Dr. Lamba has around 20 years of expertise, training and knowledge skills in the field of pharmacogenomics. Dr Lamba’s research is focused on identification, characterization and clinical validation of genomic/epigenomic markers predictive of therapeutic outcome in cancer patients with special focus on Acute Myeloid leukemia. This research spans from preclinical basic research comprising the discovery phase utilizing cell line model systems to translational/clinical phase in patient populations from multi-institute clinical trials.

Preeti Bais is an associate scientist at the computational sciences group at the Jackson Lab’s new research institute at University of Connecticut - JAX Genomics Medicine (JGM). It is an independent, nonprofit organization focusing on mammalian genetics research to advance human health. Preeti holds a PhD in bioinformatics and computational biology. She is interested in applying metabolomics for the functional genomics analysis; human embryonic (hES) and induced pluripotent stem (IPS) cells based assays for drug toxicity screening, and cancer drug efficacy testing using orthotropic mouse models of cancer.

Systems Biology, Bioinformatics, Data Mining, Machine Learning, Pattern Recognition, Metabolomics, Drug Discovery, Modeling biological systems, Metabolic network reconstruction, BioStatistics, Computational Chemistry, Computational Biology

Mei Xiao has completed her Ph.D from UMass/Boston and postdoctoral studies from University of Calgary. She is a senior software engineer of the Jackson Laboratory, a premier mammalian genetics research organization. She is interested in artificial intelligence, human-computer interaction and data visualization, bio-medical image analysis and bioinformatics.

Genetic Research, artificial intelligence, human-computer interaction and data visualization, bio-medical image analysis and bioinformatics.

Yuhua Li completed her PhD degree from Peking Union Medical College and MD from Zhengzhou University. She also received postdoctoral trainings from University of Pennsylvanian and Georgia Tech. She is the Assistant General Manager and in charge of Global Marketing & Business Development at Shanghai Biotechnology Corporation (SBC). She used to be the QA Director of SBC, VP of Otogenetics Corporation, Director of Yerkes Microarray Core Facility at Emory University and Research Scientist in Georgia Tech. She has more than 50 publications and supported hundreds of genomics projects.

Genomics & Pharmacogenomics, Human Genome Projects

Daniel Rotroff has completed his MSPH and his Ph.D. from the University of North Carolina at Chapel Hill and is currently a postdoctoral research scholar at North Carolina State University in the Department of Statistics. His graduate work was conducted within the ToxCast project at the National Center for Computational Toxicology at the US EPA and focused on predictive modeling of the estrogen receptor signaling pathway. He is currently focused on association mapping and predictive modeling for a wide range of pharmacogenomics applications.

He is currently focused on association mapping and predictive modeling for a wide range of pharmacogenomics applications.